Last reviewed · How we verify
NCT05090605
The Role of Genetic Factors in the Development of Breast Cancer in the Kazakh Population
trial testing DNA analysis in Breast Cancer in 700 participants. Completed in 20 January 2023.
20 January 2023
Quick facts
| Lead sponsor | Asfendiyarov Kazakh National Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 700 |
| Start date | 30 March 2022 |
| Primary completion | 20 January 2023 |
| Estimated completion | 20 January 2023 |
| Sites | 2 locations across Kazakhstan |
Drugs / interventions tested
- DNA analysis
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Asfendiyarov Kazakh National Medical University
Who can join
Adults 18 to 60, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a GWAS study that aims to identify possible candidate genes associate to breast cancer by exploring single nucleotide polymorphism (SNP) in a group of breast cancer, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with breast cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05090605
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DNA analysis
Trials testing the same drug.
- NCT05090644 — Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on t · completed
- NCT05088486 — The Role of Genetic Factors in the Development of Arterial Hypertension in the Kazakh Population · completed
- NCT05088499 — The Role of Genetic Factors in the Development of Epilepsy in the Kazakh Population · completed
- NCT05090631 — The Role of Genetic Factors in the Development of Atopic Dermatitis in the Kazakh Population · completed
- NCT05090618 — The Role of Genetic Factors in the Development of Myocardial Infarction in the Kazakh Population · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Asfendiyarov Kazakh National Medical University trials
Trials by the same sponsor.
- NCT06953180 — Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction · recruiting
- NCT06496022 — Comparative Analysis of Risk Factors and Prediction of Frailty Syndrome · active not recruiting
- NCT05970861 — Effect of Natural Food on Gut Microbiome and Phospholipid Spectrum of Immune Cells in COVID-19 Patients · NA · completed
- NCT05095155 — Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Ka · completed
- NCT05090644 — Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on t · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05090605 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asfendiyarov Kazakh National Medical University
- Last refreshed: 14 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05090605.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing